Sun Pharmaceutical is in the spotlight. Two key brokerages have released very divergent recommendation on the Sun Pharma share price . While one is bullish on its domestic and specialty businesses, the other flags concerns about flat productivity and future regulatory and competitive challenges.

Let’s take a look at what the brokerages have to say about this pharma sector stock and what it means for investors

Jefferies on Sun Pharma: Sees potential upside

The brokerage firm Jefferies has given a ‘Buy’ rating with a target price of Rs 2,070. This indicates a potential upside of 26% from current levels.

According to the brokerage report, Sun Pharma is well-positioned for growth, driven by volume expansion and differentiated products in India, with GLP-1 seen as a key opportunity.

See Full Page